NASDAQ:IRD Opus Genetics Q3 2025 Earnings Report $3.05 -0.22 (-6.73%) Closing price 04:00 PM EasternExtended Trading$3.18 +0.13 (+4.39%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$0.12Consensus EPS -$0.14Beat/MissBeat by +$0.02One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.08 millionExpected Revenue$3.07 millionBeat/MissBeat by +$8.00 thousandYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETUpcoming EarningsOpus Genetics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Opus Genetics Earnings HeadlinesCantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)July 11, 2026 | theglobeandmail.comOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsJuly 9, 2026 | globenewswire.comNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, produces zero carbon, and needs no fuel, no batteries, or sunlight. A crew near the Grand Canyon drilled three miles underground in just 16 days. Google signed a 15-year contract, Bill Gates invested $100 million, and the Pentagon called it priority one. On August 18th, Washington grants this energy source a competitive advantage through 2033.July 20 at 1:00 AM | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Opus Genetics (IRD) and Vertex Pharmaceuticals (VRTX)July 8, 2026 | theglobeandmail.comOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseJuly 6, 2026 | globenewswire.comRBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked SetupJuly 5, 2026 | finance.yahoo.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
